Human vascular organoids reveal clues for a potential COVID treatment
RSS
Human Vascular Organoids Reveal Clues for a Potential COVID Treatment
Human Vascular Organoids Reveal Clues for a Potential COVID Treatment
Scientists have been working tirelessly to find a cure for COVID-19, the disease caused by the novel coronavirus. Recently, a team of researchers from the University of California, San Francisco, and the Gladstone Institutes have made a breakthrough discovery that could lead to a potential treatment for the virus.
The researchers used human vascular organoids, which are miniature models of blood vessels, to study how the virus affects the human body. They found that the virus attacks the endothelial cells that line the blood vessels, causing inflammation and damage to the vascular system.
Using this information, the researchers tested a drug called A77-1726, which is currently used to treat rheumatoid arthritis. They found that the drug was able to protect the endothelial cells from the virus and reduce inflammation in the vascular system.
This discovery is significant because it provides a potential treatment option for COVID-19 patients who are experiencing vascular complications. It also sheds light on how the virus affects the human body and could lead to further research on other potential treatments.
Overall, the use of human vascular organoids in this study highlights the importance of innovative research methods in the fight against COVID-19. With continued research and collaboration, we can hopefully find a cure for this devastating disease.
[Sponsor This Article]
or [Sponsor All 100,000+ Articles At Life Technology™ Via A Corporate Sponsorship]
Life Technology™ is an Approved Google News Publisher and utilizes [ConvergenceX™], our omniscient and superluminally fast artificial intelligence, predictive analytics, and quantum logic
algorithms powered news article publishing and news headlines aggregation engine, to curate, write, SEO optimize,
and publish over 10,000 original news articles, and aggregate over 1,000,000 news article headlines per month. [ConvergenceX™] derived news articles and feeds are now available for commercial or non commercial use via [Syndication].
Since 1999 Life Technology™ has published news content entirely free of charge. Because we do not charge a
subscription fee we would kindly request that you [Make A Donation To Life Technology™] and please, do share this article with your coworkers, friends, family and favorite social media platform.
For any and all other enquiries please [contact]
us.